Seeing the potential of reducing NAA-synthesis as a treatment of CD, a 2022 study opted for a combined gene therapy treatment that expressed ASPA and knocked down Nat8L, demonstrating its ability to reverse CD in 12 weeks old mice and advocating for its potential in treating more progressed cases of CD [269]. Here, ASPA is linked to Cowden disease.